1. Home
  2. LTC vs SNDX Comparison

LTC vs SNDX Comparison

Compare LTC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LTC Properties Inc.

LTC

LTC Properties Inc.

HOLD

Current Price

$39.50

Market Cap

2.0B

Sector

Real Estate

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.34

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTC
SNDX
Founded
1992
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.6B
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
LTC
SNDX
Price
$39.50
$20.34
Analyst Decision
Hold
Strong Buy
Analyst Count
5
13
Target Price
$40.00
$38.69
AVG Volume (30 Days)
568.1K
1.5M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
5.96%
N/A
EPS Growth
23.53
11.56
EPS
1.05
N/A
Revenue
$262,854,000.00
$172,352,000.00
Revenue This Year
N/A
$107.19
Revenue Next Year
N/A
$41.88
P/E Ratio
$37.60
N/A
Revenue Growth
25.26
627.84
52 Week Low
$33.64
$13.00
52 Week High
$43.00
$25.59

Technical Indicators

Market Signals
Indicator
LTC
SNDX
Relative Strength Index (RSI) 46.75 47.70
Support Level $37.82 $19.28
Resistance Level $39.65 $22.40
Average True Range (ATR) 0.91 1.02
MACD -0.34 -0.09
Stochastic Oscillator 32.34 56.81

Price Performance

Historical Comparison
LTC
SNDX

About LTC LTC Properties Inc.

LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: